# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069311
Filing Date
2025-05-12
Accepted
2025-05-12 16:33:46
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nmra-20250331.htm iXBRL | 10-Q | 2469493
2 | EX-31.1 | nmra-ex31_1.htm | EX-31.1 | 19486
3 | EX-31.2 | nmra-ex31_2.htm | EX-31.2 | 19744
4 | EX-32.1 | nmra-ex32_1.htm | EX-32.1 | 11631
5 | EX-32.2 | nmra-ex32_2.htm | EX-32.2 | 11848
6 | GRAPHIC | img236770017_0.jpg | GRAPHIC | 1968724
| Complete submission text file | 0000950170-25-069311.txt |  | 13952560

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nmra-20250331.xsd | EX-101.SCH | 1260330
67 | EXTRACTED XBRL INSTANCE DOCUMENT | nmra-20250331_htm.xml | XML | 1566700

Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41802 | Film No.: 25935417
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)